Avecho Biotechnology hits 5-yr high, begins human trial for oral canabbis formulation

Avecho Biotechnology

23/12/2020 24:45

** Shares of Avecho Biotechnology  AVE.AX  climb as much as
116.67% to A$0.039, their highest since April 23, 2015
    ** Biotech co begins participation in observational study of
medical canabbis products, CA Clinics Observational Study
(CACOS)  urn:newsml:reuters.com:*:nGLFbYYnfD
    ** Co to test performance of oral CBD TPM formulation, used
to potentially increase oral bioavailability of canabbidiol, in
human patients 
    ** Bioavailability is the measure of the extent to which a
drug successfully reaches the intended site of action  
    ** Stock posts its biggest intraday pct gain since Dec. 19,
2018
    ** More than 20 mln shares change hands, vs the 30-day
average volume of 5 shares
    ** Stock has risen 4.5 times in value this year, as of last
close
    
  

 (Reporting by Harish Sridharan in Bengaluru)
 ((harish.sridharan@thomsonreuters.com))